Campus alert status is yellow: For the latest campus alert status, news and resources, visit

Search Close Search
Search Close Search
Page Menu

Donna M Ambrosino

UMassMed Faculty Page


Title: Human Antibodies Against Rabies and Uses Thereof. UMMS14-48; Patent Pending. 

  • New neutralizing monoclonal antibodies for rabies RAB2 and RAB3. Can be used together or in combination with RAB1, these antibodies have demonstrated superior performance in the treatment of rabies in comparison to other individually tested antibodies and will cover variety of zootonic strains.

Title: Monoclonal Antibodies to sFlt1 and Uses Thereof. UMMS13-51; Patent Pending.

  • This technology discloses novel antibodies and antibody fragments that bind soluble fms-like tyrosine kinase 1 (sFlt1) in an isoform specific manner. Further disclosed are assays employing sFlt1 antibodies to evaluate preeclampsia in pregnant women.


  • This invention discloses a panel of newly discovered human monoclonal antibodies against human SOD1 protein.  There are two types of SOD1 antibodies available: 1) one that binds to all forms of SOD1 and 2) one that binds to the misfolded form of SOD1. Mutated SOD1 is associated with 20% of inheritable forms of Amyotrophic Lateral Sclerosis (ALS) and blocking its function is protective. These monoclonal antibodies present a unique therapeutic opportunity to treat ALS with an immunologically targeted approach. 


Innovation TopicsBiologicsInfectious DiseasePost-exposure prophylacticRabiesAntibodyDiagnosticsEclampsia/PreeclampsiaObstetricsNeuronal SOD1Amyolateral Sclerosis (ALS)Human monoclonal